Pharmacokinetics of cefixime in children with urinary tract infections after a single oral dose

被引:8
作者
Mamzoridi, K
Kasteridou, N
Peonides, A
Niopas, I
机构
[1] ARISTOTELIAN UNIV THESSALONIKI,DEPT PHARM,GR-54006 THESSALONIKI,GREECE
[2] ARISTOTELIAN UNIV THESSALONIKI,SCH MED,ACHEPA HOSP,PAEDIAT CLIN 4,GR-54006 THESSALONIKI,GREECE
来源
PHARMACOLOGY & TOXICOLOGY | 1996年 / 78卷 / 06期
关键词
D O I
10.1111/j.1600-0773.1996.tb00229.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics of cefixime. a third-generation broad-spectrum cephalosporin, were determined following administration of a 8 mg/kg single oral dose of cefixime suspension to six children with urinary tract infections, ages from 6 to 13 years and weights from 17 to 60 kg. Blood samples for determination of plasma cefixime concentrations were obtained for up to 12 hr and complete urine collections were obtained for urinary excretion of unchanged parent drug for up to 24 hr after administration. Plasma and urine concentrations of cefixime were determined using a reversed phase HPLC assay and pertinent pharmacokinetic parameters were estimated by model-independent standard methods. Mean peak plasma concentration was 4.04 mu g/ml and was reached after 3.2 hr. The mean area under the plasma concentration time curve was 33.07 mu g.hr/ml and the mean elimination half-life was 3.91 hr. The mean apparent total clearance was 4.74 ml/min./kg and about 15% of the dose administered was recovered unchanged in urine. In conclusion, the estimated pharmacokinetic values of cefixime were comparable to those observed in healthy adult subjects based on equivalent mg/kg doses. Plasma and urine concentrations of the drug were well above the reported minimal plasma and urinary concentrations for most common urinary tract pathogens for up to 12 and 24 hr after administration, respectively.
引用
收藏
页码:417 / 420
页数:4
相关论文
共 16 条
[1]   THE PHARMACOKINETIC AND BACTERICIDAL CHARACTERISTICS OF ORAL CEFIXIME [J].
BRITTAIN, DC ;
SCULLY, BE ;
HIROSE, T ;
NEU, HC .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 38 (05) :590-594
[2]   RELATIONSHIP BETWEEN RENAL-FUNCTION AND DISPOSITION OF ORAL CEFIXIME [J].
DHIB, M ;
MOULIN, B ;
LEROY, A ;
HAMEAU, B ;
GODIN, M ;
JOHANNIDES, R ;
FILLASTRE, JP .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 41 (06) :579-583
[3]   DETERMINATION OF CEFIXIME IN BIOLOGICAL SAMPLES BY REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
FALKOWSKI, AJ ;
LOOK, ZM ;
NOGUCHI, H ;
SILBER, BM .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1987, 422 :145-152
[4]   PHARMACOKINETIC PROFILE OF CEFIXIME IN MAN [J].
FAULKNER, RD ;
YACOBI, A ;
BARONE, JS ;
KAPLAN, SA ;
SILBER, BM .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1987, 6 (10) :963-970
[5]   PHARMACOKINETICS OF CEFIXIME AFTER ONCE-A-DAY AND TWICE-A-DAY DOSING TO STEADY-STATE [J].
FAULKNER, RD ;
BOHAYCHUK, W ;
DESJARDINS, RE ;
LOOK, ZM ;
HAYNES, JD ;
WEISS, AI ;
SILBER, BM .
JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 27 (10) :807-812
[6]   BIOEQUIVALENCY OF SOLID ORAL DOSAGE FORMS OF CEFIXIME [J].
FAULKNER, RD ;
SIA, LL ;
LOOK, ZM ;
BARONE, JS ;
FORBES, SJ ;
WEISS, AI ;
SILBER, BM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1988, 43 (1-2) :53-58
[7]   ANTIMICROBIAL THERAPY - COST-BENEFIT CONSIDERATIONS [J].
GUGLIELMO, BJ ;
BROOKS, GF .
DRUGS, 1989, 38 (04) :473-480
[8]   IMPORTANCE OF PATIENT COMPLIANCE IN EFFECTIVE ANTIMICROBIAL THERAPY [J].
HUSSAR, DA .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1987, 6 (10) :971-975
[9]  
KAMIMURA T, 1985, ANTIMICROB AGENTS CH, V25, P98
[10]   CLINICAL PHARMACOKINETICS IN INFANTS AND CHILDREN - A REAPPRAISAL [J].
KEARNS, GL ;
REED, MD .
CLINICAL PHARMACOKINETICS, 1989, 17 :29-67